Haleon plc (HLN) is a publicly traded company in the Healthcare — Drug Manufacturers - Specialty & Generic industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region.
Is Haleon plc stock overvalued or undervalued in 2026?
Haleon plc (HLN) trades at 20.2× earnings (P/E), below the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $15 (+51 %).
Kaplio overview: Haleon plc
Market cap $44B · 52 weeks $9 – $11 (11 % below the high) · P/E 20.2× · 2027 expected P/E 16.4× · Dividend 2.0 % · Next earnings March 4, 2027 · expected EPS $0.28 · Closing price, Oct 28 · accounts published Jul 30.
- Valuation: P/E 20.2× (cheap).
- Business: ROIC 6 % (weak).
- Balance sheet: Net debt/EBITDA 2.5× (watch).
- Earnings: 6 of 8 (on track).
What would it be worth at its usual multiples?
At its sector median (30.4×) $15 (+51 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 2 of 7 pass
- R&D / Revenue 2.8 %, fails.
- ROIC 6.5 %, fails.
- 5y EPS growth 8.0 %, borderline.
- Gross margin 63.3 %, borderline.
- Net debt / EBITDA 2.5×, borderline.
- FCF / Net Income 120.9 %, passes.
- P/E vs own 10y history 20.2×, passes.
Against its peers (reference peers) — Haleon plc: P/E 20.2×; EV/EBITDA 13.9×; ROIC 6.5 %; $44.0B. Kenvue Inc. (P/E 22.2×; EV/EBITDA 14.2×; ROIC 10.1 %; $37.1B), Colgate-Palmolive Company (P/E 36.3×; EV/EBITDA 21.0×; ROIC 29.9 %; $73.1B), Church & Dwight Co., Inc. (P/E 33.8×; EV/EBITDA 21.3×; ROIC 10.8 %; $24.8B).
Expensive or cheap against its last 3 years?
P/E at each close: today 20.2× · median 12.5× · minimum 8.7× · maximum 20.2× · cheap below 11.9× · expensive above 13.1×. It has been cheaper than today 100% of the time over its last 3 years.
Dividend
tight (only raised recently) · Yield 2.0 % ($0.18 per ADS in 2025) · Years raising it 2 · 5-year growth -24 % a year · Free cash flow coverage 3.7× · With $1,000 invested today you'd collect $19.90 a year ($1.66 a month).
Investor methods verdict
Would Buffett approve Haleon today?
The Buffett Method would not approve Haleon today: it fails its quality rules. Business quality: 78 out of 100 (price not included). Kaplio assessment with data from the week of 2026-10-26; not investment advice.
Would Peter Lynch approve Haleon today?
The Lynch Method would wait for a better price for Haleon: P/E 20.2 with 8% growth; it asks that the P/E not exceed growth. Business quality: 100 out of 100 (price not included). Lynch classifies it as a stalwart. Kaplio assessment with data from the week of 2026-10-26; not investment advice.
Profitability
| Return on Equity | 9.89% |
| Return on Invested Capital | 6.46% |
| Return on Assets | 4.98% |
| Gross Margin | 65.57% |
| Operating Margin | 21.35% |
| Net Margin | 14.55% |
Financial Health
| Debt / Equity | 0.50 |
| Current Ratio | 0.69 |
| Piotroski F-Score | 8 |
| Altman Z-Score | 2.51 |
Price Performance
| 1 month | +10.25% |
| 3 months | +1.32% |
| Year-to-date | -1.09% |
| 1 year | +10.50% |
| 3 years | +24.69% |
Dividend History
Paid in the last 12 months: $0.1980 per share in 2 payments.
| Date | Amount |
|---|---|
| 2026-08-14 | $0.0647 |
| 2026-04-10 | $0.1333 |
| 2025-08-15 | $0.0598 |
| 2025-04-25 | $0.1166 |
| 2024-08-16 | $0.0514 |
| 2024-03-14 | $0.1064 |
| 2023-08-24 | $0.0460 |
| 2023-03-16 | $0.0577 |
Amounts adjusted for stock splits.
Related companies: GSK · CL · KVUE · CHD · PRGO
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of HLN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks